New mRNA vaccine aims to outsmart flu by targeting its hidden parts

NCT ID NCT07703514

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This Phase 1 trial tests experimental mRNA vaccines designed to protect against many types of influenza A by targeting a stable part of the virus. Healthy adults aged 18 to 59 receive one or two doses of the vaccine candidates, alone or in combination. The study checks for side effects and measures the immune response in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA chimeric hemagglutinin vaccine candidates (cH8/1, cH5/1, cH15/3, cH4/3) targeting influenza A group 1 and group 2
What this could lead to: If successful, this approach could lead to a more broadly protective influenza vaccine that targets multiple strains of influenza A.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so safety and immune response are still being explored. The vaccine may not produce strong or lasting immunity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza swine influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health

Baltimore, Maryland, 21201-1509, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.